Projects per year
Personal profile
Biography
Professor Jake Shortt is the Head of Haematology Research at the School of Clinical Sciences and clinical lead at Monash Haematology for myeloid leukaemia, myelodysplasia and T-cell lymphoma. He is Principal Investigator on a range of clinical trials for T-cell lymphoma and myeloid malignancies, conducted through the Monash Haematology clinical trials unit.
Professor Shortt is the recipient of a Medical Research Future Fund Career Development Fellowship as part of the Next Generation Clinical Researchers Program. His strong translational work in the School of Clinical Sciences is focused on strategies incorporating epigenetic drugs with immunotherapy in haematological cancers, particularly lymphoma and multiple myeloma. He heads the Blood Cancer Therapeutics laboratory within the Monash Health Translation Precinct, facilitating bench-to-bedside research in order to progress these new treatments into the haematology clinic.
In addition to his clinical and research roles, Professor Shortt is the Chair of the Laboratory Sciences Working Party of the Australasian Leukaemia and Lymphoma Group (ALLG) and Deputy Chair of the ALLG Scientific Advisory Committee.
Clinical activities
Professor Shortt is clinical lead at Monash Health for myeloid leukaemia, myelodysplasia and T-cell lymphoma. He is also the Deputy Unit Head of Laboratory Haematology. He attends the Monash Haematology myeloid disorders clinic and looks after Haematology inpatients at Monash Health. Professor Shortt is the Principal Investigator at Monash Health for a range of clinical trials in leukaemia, myelodysplasia, myeloproliferative disorders and T-cell lymphoma.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
External positions
Honorary Clinical Professor, University of Melbourne
1 Jan 2022 → …
Honorary Principal Fellow, University of Melbourne
31 Jan 2019 → 31 Dec 2021
Honorary Senior Research Scientist, Peter MacCallum Cancer Centre
1 Oct 2015 → …
Consultant Haematologist, Monash Health
1 Feb 2008 → …
Research area keywords
- Cancer Immunology
- Epigenetics
- Leukemia
- Lymphoma
- Molecular Oncology
- Myelodysplasia
- Myeloma
- Thrombotic thrombocytopenic purpura
- cMYC
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Dual-targeted inhibitors of BET bromodomains and PI3-kinase for cancer therapy.
1/02/22 → 1/02/24
Project: Research
-
Genetically defining and pharmacologically exploiting new oncogenic dependencies in Myc-driven lymphoid cancer
1/01/22 → 31/12/26
Project: Research
-
A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT-232 in Subjects With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), or Post–Essential Thrombocythemia MF (Post–ET-MF) who are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment
26/08/21 → 25/08/26
Project: Research
-
Cardiovascular Safety of Nilotinib in Alzheimer Disease
Tan, S., Baggio, D., Shortt, J. & Ko, B., Jan 2021, In: Annals of Neurology. 89, 1, p. 196 1 p.Research output: Contribution to journal › Letter › Other › peer-review
-
Cardiovascular Safety of Nilotinib in Parkinson's Disease
Tan, S., Baggio, D., Shortt, J. & Ko, B., Sep 2021, In: Movement Disorders. 36, 9, p. 2217 1 p.Research output: Contribution to journal › Letter › Other › peer-review
-
Excellent outcomes in older patients with primary CNS lymphoma treated with R-MPV/cytarabine without whole brain radiotherapy or autologous stem cell transplantation therapy
Tatarczuch, M., Paul, E., Gilberston, M., Gregory, G. P., Tam, C., Quach, H., Bazargan, A., Filshie, R., Ku, M., Tey, A., Shortt, J. & Opat, S., 2 Jan 2021, In: Leukemia and Lymphoma. 62, 1, p. 112-117 6 p.Research output: Contribution to journal › Article › Research › peer-review
3 Citations (Scopus) -
Excellent outcomes of transformed lymphomas in the rituximab era without autologous stem cell transplantation: an Australian single-centre experience
Tedjaseputra, A., Gilbertson, M., Low, M., Fedele, P. L., Kumar, B., Simpson, I., Grigoriadis, G., Shortt, J., Opat, S. & Gregory, G. P., Nov 2021, In: Internal Medicine Journal. 51, 11, p. 1285-1834Research output: Contribution to journal › Article › Research › peer-review
-
Impact of COVID-19 Pandemic Isolation Measures on the Rate of Non-COVID Infections in Hematology Patients
Miller, J., Opat, S., Shortt, J., Kotsanas, D., Dendle, C. & Graham, M., Feb 2021, In: Infection Control and Hospital Epidemiology. 42, 2, p. 233-235 3 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access
Prizes
-
Albert Baikie Memorial Medal (2011)
Shortt, Jake (Recipient), 2011
Prize: Prize (including medals and awards)
-
Joseph F Sambrook Prize for Research Excellence (2015)
Shortt, Jake (Recipient), 2015
Prize: Prize (including medals and awards)
-
-
Prize for Preclinical Myeloma Research (2015)
Shortt, Jake (Recipient), 2015
Prize: Prize (including medals and awards)
Activities
-
Deputy Chair - ALLG Scientific Advisory Committee
Jake Shortt (Chair/ Co-Chair)
2020 → …Activity: External Academic Engagement › Committees and working groups
-
Australasian COVID19 Trial (ASCOT) Therapeutic Advisory Committee
Jake Shortt (Member)
2020 → …Activity: External Academic Engagement › Committees and working groups
-
European Hematology Association (External organisation)
Jake Shortt (Member)
2018Activity: Industry, Government and Philanthropy Engagement and Partnerships › Membership of networks of excellence
-
Chemical Probes Portal (External organisation)
Jake Shortt (Member)
2017 → …Activity: Industry, Government and Philanthropy Engagement and Partnerships › Membership of an advisory panel/policy group/ board
-
Standing Research Sub-Committee - Cancer Council Victoria
Jake Shortt (Member)
2017Activity: External Academic Engagement › Committees and working groups